Arturo Urrios
InvestorLeads early-stage investments and company creation at Ysios Capital
Barcelona, Catalonia, Spain
About
Arturo Urrios leads early-stage investments and company creation at Ysios Capital. He previously worked at M Ventures and Wellington Parties, where he was involved in financings including Riffyn, Plexium, eGenesis, Themis Biosciences and Seamless Therapeutics. He helped create Seamless Therapeutics in 2022, leading its business development and corporate strategy and securing a collaboration with Lilly. He holds a BSc in Human Biology, an MSc in Biomedical Research, an MBA, and a PhD in Biomedicine, and co-founded the YVC Collective.
Contact· self-published, not guessed
Invests in
Biotech
Experience
- Ysios CapitalPartnercurrent2026 — presentBarcellona
- Ysios CapitalVenture Partner2025 — 2026
- BioInnovation InstituteProgram Advisorcurrent2020 — present
- Wellington Partners Life SciencesVenture Advisor2023 — 2025
- Wellington Partners Life SciencesPrincipal2022 — 2023Munich, Baviera, Alemania
- Wellington Partners Life SciencesSenior Associate2020 — 2022Munich y alrededores, Alemania
- Wellington Partners Life SciencesAssociate2019Múnich y alrededores
- Fundación "la Caixa"CaixaResearch Consolidate advisor2022 — 2025
- Seamless TherapeuticsFounding Member2023 — 2024Dresde, Sajonia, Alemania
- YVC CollectiveFounding Member2021 — 2024
- M VenturesLife Science Analyst2018 — 2019Ámsterdam y alrededores, Países Bajos
- Universitat Pompeu Fabra - UPFPostdoctoral Researcher at Cell Signaling Research Group2017 — 2018Barcelona
- Universitat Pompeu Fabra - UPFPHD Student at Cell Signaling Research Group2013 — 2017Barcelona
- University of WashingtonFolch lab - Department of Bioengineering2015 — 2016Seattle, WA
- Universitat Pompeu Fabra - UPFBiomedicine Master Student2012 — 2013Barcelona
Skills & more
Biología molecular11Cultivos celulares8Investigación y desarrollo3Impresión 3DBioquímica6Ciencias naturales4Biología celular1Genética1Ciencias5Reacción en cadena de la polimerasaWestern blot1Bioinformática
+12 more
EstadísticaBiotecnologíaMicrosoft OfficeClonación de genesInglésPCR en tiempo realAnálisis de datosGenómicaLife SciencesMolecular BiologyAutodesk InventorResearchLanguages Catalán · Español · Inglés
From Arturo's professional profile.
Investments
Investor
eGenesisPlexiumRiffynSeamless TherapeuticsThemis Biosciences
Per the firm's website.
Colleagues at Ysios Capital
Almudena Méndez
Associate at Ysios Capital
Antoni Ribas
Venture Partner at Ysios Capital
Carlos Garcia-Echeverria
Venture Partner at Ysios Capital
Carlos Paya
Venture Partner at Ysios Capital
Catalina Cuchy
Executive Assistant at Ysios Capital
Cristina Garmendia
General Partner at Ysios Capital
David L. Lacey
Venture Partner at Ysios Capital
Guillem Laporta
Partner at Ysios Capital
Frequently asked questions
- Who is Arturo Urrios?
- Arturo Urrios leads early-stage investments and company creation at Ysios Capital. He previously worked at M Ventures and Wellington Parties, where he was involved in financings including Riffyn, Plexium, eGenesis, Themis Biosciences and Seamless Therapeutics. He helped create Seamless Therapeutics in 2022, leading its business development and corporate strategy and securing a collaboration with Lilly. He holds a BSc in Human Biology, an MSc in Biomedical Research, an MBA, and a PhD in Biomedicine, and co-founded the YVC Collective.
- Where does Arturo Urrios work?
- Arturo Urrios is Leads early-stage investments and company creation at Ysios Capital.
- What does Arturo Urrios invest in?
- Arturo Urrios invests in Biotech.
- What companies has Arturo Urrios invested in?
- Investments tracked here include eGenesis, Plexium, Riffyn, Seamless Therapeutics, Themis Biosciences.
- Where did Arturo Urrios go to school?
- Arturo Urrios studied at UPF Barcelona School of Management (Executive MBA); Universitat Pompeu Fabra (PhD in Biomedicine. La Caixa Fellowship); University of Washington.
Same school
Also attended UPF Barcelona School of Management8
Montse VendrellPartner at Asabys PartnersOriol RosManaging Partner at Kalonia Venture PartnersRoma JelinskaiteManaging Director at Criteria Venture TechGemma GuinartPrincipal at Invivo Capital PartnersJaime de OlaortuaInvestor at ActyusRoma JelinskaiteStrategic Committee — Managing Director at Criteria Venture Tech at 33N
+ 2 more
Also attended Universitat Pompeu Fabra82
Aniol BrosaGeneral Partner at Inveready Technology Investment GroupErnest GassóDirector at Inveready Technology Investment GroupIgnacio PuigGeneral Partner at Inveready Technology Investment GroupTomek LepkaInvestment Manager at Keen Venture PartnersAgustina NietoLegal Counsel at Nauta CapitalJosep Ll. SanfeliuCo-founder and managing partner at Asabys Partners
+ 76 more
Also attended University of Washington277
Andrew ChenGeneral Partner at Andreessen HorowitzArvind JainFounder & CEO of GleanJane MooneyCo-founder & VP, Strategy and Finance at Collaborative RoboticsVictoria TreygerGeneral Partner at Felicis VenturesAndrewAdvisor at Clear VenturesJoe HorsmanInvestor at Madrona Venture Group
+ 271 more
Shared employers
Also worked at Ysios Capital17
Josep Ll. SanfeliuCo-founder and managing partner at Asabys PartnersSylvain SachotPartner at Asabys PartnersIsabel JimenezPrincipal at Asabys PartnersJoël Jean-MairetManaging Partner at Ysios CapitalJulia SalaverríaManaging Partner at Ysios CapitalKaren WagnerManaging Partner at Ysios Capital
+ 11 more
Also worked at BioInnovation Institute8
Sten VerlandVenture Partner at Sunstone CapitalThomas NagyOperational Partner at Astanor VenturesKarolina ZapadkaSenior Investment Manager at Parkwalk AdvisorsAlexander DemoulinAssociate at Bioqube VenturesRegina HoditsManaging Director at Angelini VenturesCarolina VillaPrincipal at Nucleus Capital
+ 2 more
Also worked at Wellington Partners Life Sciences15
Eric ArchambeauSenior Managing Partner at Astanor VenturesFelix HaasInvestment Team at 10x FoundersLinus DahgManaging Partner at InventureFlorian ErberGeneral Partner and Founder at Ananda Impact VenturesJohannes von BorriesManaging Partner at UVC PartnersPeter DudekPresident at MRL Ventures Fund
+ 9 more
